PsyLabs

PsyLabs is at the forefront of the emerging psychedelic medicine industry, operating legal cultivation and extraction facilities for psychoactive compounds in Southern Africa. The company specializes in the production of pharmaceutical-grade psychedelic substances, including psilocybin, psilocin, mescaline, ibogaine, and DMT, for use in medical research and clinical trials.

With a focus on quality and regulatory compliance, PsyLabs has established itself as a trusted supplier to research partners and pharmaceutical companies worldwide. Their state-of-the-art facility is ISO22000 certified and audited by the British Standards Institution, ensuring the highest standards of production and safety.

PsyLabs' proprietary extraction and refinement processes are designed to produce purified Active Pharmaceutical Ingredients (APIs) with comprehensive supporting documentation. This positions the company to meet the stringent requirements of drug development, including readiness for Investigational New Drug (IND) applications.

In addition to their core psychedelic products, PsyLabs has diversified into functional mushroom wellness products under the GoodMind brand. These non-psychoactive adaptogenic fungi offer stress-relieving and general wellness benefits, tapping into the growing market for natural health solutions.

With successful exports to multiple countries and partnerships with Contract Development & Manufacturing Organizations, PsyLabs is well-positioned to drive innovation in mental health treatment and contribute to the advancement of psychedelic medicine on a global scale.